A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs BLU 554 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 02 Aug 2017 According to a Blueprint Medicines media release, updated data (data cut-off date of April 20, 2017) from this clinical trial will be presented at the ESMO 2017 on September 10, 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Planned number of patients changed from 70 to 130.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top